



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Change of Nominated Adviser**

**London: Tuesday, 28 August 2012:** Chi-Med today announces that it has appointed Panmure Gordon (UK) Limited as its nominated adviser with effect from 28 August 2012. This role is in addition to its existing role as joint corporate broker to Chi-Med, alongside UBS Limited.

The directors of Chi-Med would like to express their thanks to Lazard & Co., Limited for its advice and support over the years.

**Ends**

**Enquiries**

<b>Chi-Med</b> Christian Hogg, CEO	Telephone: +852 2121 8200
<b>Citigate Dewe Rogerson</b> Anthony Carlisle David Dible	Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919
<b>Panmure Gordon (UK) Limited</b> Richard Gray Andrew Potts Grishma Patel	Telephone: +44 20 76148383

**About Chi-Med**

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.